Aditxt Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.96 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $0.00Price as of 30 Sep 2026 Data confidenceNot applicable Market Cap $3.9M Enterprise Value $7M Shares Outstanding 998M diluted All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Aditxt, Inc. operates as an extremely high-risk, pre-revenue life sciences platform company with severe going concern doubts, substantial historical net losses, and a history of highly dilutive capital raises and reverse stock splits. While the proposed spin-off of its precision oncology subsidiary, Ignite Proteomics, via a SPAC merger at an implied $150 million valuation represents a potential mechanism to unlock asset value, the parent company's standalone financial health remains exceptionally weak. With a net loss of $15.95 million on just $12,000 of revenue in Q1 2026, and a history of frequent reverse splits (including a 1-for-27 split in May 2026), retail investors face extreme risk of capital destruction and ongoing dilution. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The Ignite Proteomics SPAC merger fails to close due to inability to meet the minimum $15 million cash condition or secure the required $7.5 million in transaction financing. Aditxt's stockholders' equity falls back below the $2.5 million Nasdaq minimum, triggering immediate delisting proceedings. Lacking access to capital, the company is forced to halt operations or undergo restructuring, rendering the common stock virtually worthless. Base CaseCentral scenario The proposed SPAC merger of Ignite Proteomics successfully closes by late Q3 2026, establishing Ignite as an independent NYSE-listed entity. Aditxt retains a equity stake or receives transaction proceeds, temporarily stabilizing its balance sheet. However, the parent company continues to burn cash rapidly on its remaining early-stage programs (Adimune, Adivir, Adifem) with minimal commercial revenue, necessitating further dilutive equity offerings or ATM utilization to maintain Nasdaq listing compliance. Bull CaseUpside scenario The successful spinoff and NYSE listing of Ignite Proteomics unlocks substantial value for Aditxt shareholders, while Adimune's upcoming FDA submissions for ADI-100 validate its immune reprogramming platform, driving long-term enterprise value. Scenarios reflect our research view at the research date. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |